Business
Aelis Farma Obtains Regulatory Approval of the Phase 2B Trial With AEF0217 in People With Down Syndrome
BORDEAUX, France, December 02, 2025--Regulatory News: Aelis Farma (ISIN: FR0014007ZB4 – Ticker: AELIS), a clinical-stage biopharmaceutical company specializing in the development of treatments for brain and peripheral diseases involving the CB1 receptor, today announces that it has received the approvals from the European Medical Agency (EMA) and from the competent authorities and ethics committees in France, Italy and Spain of the protocol of the Phase 2B clinical study of AEF0217 for the treat
About this update from Aelis Farma Sa
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":252,"url":"https://media.zenfs.com/en/business-wire.com/06d01f292d931814512dd4bc8b40dbd3"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/wMZAJcHHgPNar3GLs6xNqg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTUwNDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/06d01f292d931814512dd4bc8b40dbd3","width":480,"height":252}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"AEF0217 is a first-in-class CB1 receptor Signalling Specific inhibitor (CB1-SSi) developed as a potential first pharmacological treatment for impairments in adaptive behaviours and cognition in neurodevelopmental disorders, a major unmet medical need.","length":251,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Regulatory approvals have been obtained via the EU Clinical Trials Information System (CTIS) and from the relevant national competent authorities and ethics committees in France, Italy and Spain for a multinational Phase 2B dose-finding trial in 188 participants with Down syndrome aged 16 to 32 years.","length":302,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"The Phase 2B trial (AEF0217-201) is designed to confirm and extend the positive Phase 1/2 data with AEF0217, which showed a very favourable safety and pharmacokinetic profile, and statistically significant improvements in adaptive behaviours and brain activity in young adults with Down syndrome. ","length":296,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Recruitment is expected to start speedily, last-participant-last-visit is anticipated in Q1 2027 and preliminary results should be available around mid-2027.","length":157,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"The company has implemented several measures that extend its cash runway up to beginning of 2028 included and will pursue a further extension of its financial visibility. ","length":170,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":1176,"olType":false},{"type":"text","content":"BORDEAUX, France, December 02, 2025--(BUSINESS WIRE)--Regulatory News:","length":70,"tagName":"p"},{"type":"text","content":"Aelis Farma (ISIN: FR0014007ZB4 – Ticker: AELIS), a clinical-stage biopharma...